Geert Kleinnibbelink

RV Strain in Pulmonary Hypertension 6 147 Table 3 . Population data extracted from the included studies First author Study design Study population WHO group NYHA class PH specific therapy at inclusion Follow-up (y) Endpoint Combined endpoint da Costa et al. 7 NR N: 66 Age: 45±15 Female sex: 83% 1 (n=66) I-II (67%) III (33%) Bosentan and ambrisentan (n=16) Sildenafil (n=31) Calcium channel blockers (n=2) Combined therapy (n=17) 3.3y Cardiovascular mortali- ty and hospitalization for worsening of PH Fine et al. 8 Prospective N: 406 Age: 59±16 Female sex: 65% 1 (n=300) 3 (n=58) 4 (n=48) I (20%) II (34%) III (38%) IV (8%) Prostacyclin (n=50) Endothelin receptor antagonist (n=82) Phosphodiesterase-5 inhibitor (n=89) 1.5y Cardiopulmonary death and cardiopul- monary events Giusca et al. 11 NR N: 32 Age: 39±15 Female sex: 69% 1 (n=29) 4 (n=3) II (40.6%) III (56.2%) IV (3.2%) Bosentan (n=11) Sildenafil (n=16) Combined (n=5) 1.2y All-cause mortality and treatment failure Moceri et al. 29 † Prospective N: 104 Age: 66±4 Female sex: 56% 1 (n=65) 3 (n=26) 4 (n=11) 5 (n=2) II (36.5%) III (44.2%) IV (19.3%) Advanced targeted PAH therapy (n=87) 0.6y PH related mortality Murata et al. 21 Retrospective N: 100 Age: 51±17 Female Sex:74% 1 (n=72) 4 (n=28) I (22%) II (46%) III (32%) Phosphodiesterase-5 inhibitor (n=69) Endothelin receptor antagonist (n=56) Prostacyclins (n=26) Calcium channel blockers (n=11) Vitamin K antagonist (n=28) 1.2y All-cause mortality, hospitalization and intervention for dete- rioration right-sided heart-failure Park et al. 10 Retrospective N: 51 Age: 48±14 Female sex: 78% 1 (n=51) I (4%) II (61%) III (35%) Phosphodiesterase-5 inhibitor (n=29) Endothelin receptor antagonist (n=26) Prostacyclins (n=32) Calcium channel blockers (n=9) 3.8y Clinical events Unlu et al. 26* Retrospective N: 62 Age: 61±15 Female sex: 68% 1 (n=33) 4 (n=29) I (6.5%) II (25.8%) III (58%) IV (9.7%) Treatment naïve 3.8y All-cause mortality and heart or lung t ransplantation